Advancing proteomics and machine learning in the clinic:an editorial on“Noninvasive proteomic biomarkers for alcohol-related liver disease”  

作　　者：Courtney D.McGinnis Brenton I.M.Graham Peter S.Harris Kristofer S.Fritz 

机构地区：[1]Skaggs School of Pharmacy and Pharmaceutical Sciences,University of Colorado Anschutz Medical Campus,Aurora,CO,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第5期762-765,共4页肝胆外科与营养（英文）

基　　金：funded in part by National Institutes of Health grants NIH R21AA026928,R01DK109964,and AA029218(K.S.F)and by NIH/NCATS Colorado CTSA Grant Number TL1 TR002533(C.D.M.).Contents are the authors’sole responsibility and do not necessarily represent official NIH views.

摘　　要：Alcohol-associated liver disease(ALD)is increasingly prevalent throughout the world(1).It remains the leading cause of liver-related morbidity and mortality worldwide and contributes to approximately 6%of global deaths(2).ALD encompasses a wide range of hepatic pathologies,including steatosis,steatohepatitis,fibrosis,and cirrhosis(3).Given the severe lack of therapeutic interventions available to reverse the progression of ALD,it is currently the leading indication for liver transplantation(4).Advancements within the field are needed to identify diagnostic biomarkers for early detection and to develop therapeutics to ameliorate hepatic dysfunction and pathologies associated with ALD.

关 键 词：HEPATIC liver mortality 

分 类 号：R575.5[医药卫生—消化系统] TP181[医药卫生—内科学]